Heron Therapeutics, Inc. /DE/ last reported quarterly results on Aug 10, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $37.7 million (+1.3% year over year) and diluted EPS of -$0.03. It usually reports 35–57 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 3, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Nov 4, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–57 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 10, 2026
41 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
38
+1.3%
|
-5
-130.5%
|
-0.03
-50.0%
|
|
May 11, 2026
41 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
35
-10.8%
|
-8
-407.8%
|
-0.04
-500.0%
|
|
Feb 26, 2026
57 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
41
-0.5%
|
-3
-180.6%
|
-0.02
-165.7%
|
|
Nov 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
38
+16.5%
|
-17
-260.9%
|
-0.10
-233.3%
|
|
Aug 8, 2025
39 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
37
+3.3%
|
-2
+74.2%
|
-0.02
+66.7%
|
|
May 6, 2025
36 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
39
+12.2%
|
3
+183.4%
|
0.01
+150.0%
|
|
Feb 27, 2025
58 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
41
+19.1%
|
4
+134.2%
|
0.02
+133.7%
|
|
Nov 12, 2024
43 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
33
+4.4%
|
-5
+80.6%
|
-0.03
+82.4%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HRTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 818033
- Former names
- AP PHARMA INC /DE/ (until Jan 7, 2014); ADVANCED POLYMER SYSTEMS INC /DE/ (until Apr 6, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.